Taijin Shi
Xiaoyan Cui
Junlin Wang3
Jiayin Meng- 1College of Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
- 2Pharmacy Department, Jinan Huaiyin People’s Hospital, Jinan, China
- 3Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, China
- 4Department of Pharmacy, Jinan Licheng District Liubu Town Health Centre, Jinan, China
- 5Department of Pharmacy, Jinan Second People’s Hospital, Jinan, China
A Correction on
Crosstalk between the tumor immune microenvironment and metabolic reprogramming in pancreatic cancer: new frontiers in immunotherapy
By Shi J, Cui X, Wang J, Liu G, Meng J and Zhang Y (2025). Front. Immunol. 16:1564603. doi: 10.3389/fimmu.2025.1564603
There was an error in affiliation 3. Instead of “Department of Pharmacy, Shandong University Second People’s Hospital, Jinan, China”, it should be “Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan, China”.
Author “Taijin Shi” was erroneously spelled as “Jintai Shi”.
The Author Contributions Statement has been corrected to read:
“TS: Writing – original draft, Writing – review & editing. XC: Writing – original draft, Writing – review & editing. JW: Supervision, Writing – review & editing. GL: Methodology, Writing – original draft. JM: Validation, Writing – original draft. YZ: Supervision, Writing – original draft, Writing – review & editing.”
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: PC, time, metabolic reprogramming, mechanisms, immunotherapy
Citation: Shi T, Cui X, Wang J, Liu G, Meng J and Zhang Y (2025) Correction: Crosstalk between the tumor immune microenvironment and metabolic reprogramming in pancreatic cancer: new frontiers in immunotherapy. Front. Immunol. 16:1643932. doi: 10.3389/fimmu.2025.1643932
Received: 09 June 2025; Accepted: 07 July 2025;
Published: 25 July 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Shi, Cui, Wang, Liu, Meng and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yingjie Zhang, aWN5Nzg5QDEyNi5jb20=; Jiayin Meng, YXNkZmcwMTAyMDJAMTYzLmNvbQ==
†These authors share first authorship